CareMax, Inc. (NASDAQ: CMAX; CMAXW), a leading technology-enabled provider of value-based care to seniors, announced today financial results for the third quarter ended September 30, 2021.
Third Quarter 2021 Results1
- GAAP total revenue was $104.6 million for the third quarter of 2021 and $177.5 million for the nine-months ended September 30, 2021, up 330% and 136% year-over-year, respectively.
- Medicare Advantage membership as of September 30, 2021 was 26,500, up over 340% compared to Medicare Advantage membership as of September 30, 2020; total membership as of September 30, 2021 was 68,500, up over 1,000% compared to total membership as of September 30, 2020.
- Medical Expense Ratio was 75.4% for the third quarter of 2021, compared to 71.4% for the third quarter of 2020.2
- GAAP net loss was $2.9 million for the third quarter of 2021, or $(0.03) per diluted share, and $8.9 million, or $(0.22) per diluted share, for the nine-months ended September 30, 2021.
- Adjusted EBITDA was $1.2 million for the third quarter of 2021 and $9.1 million for the nine-months ended September 30, 2021, pro forma for the business combination; excluding estimated impacts from COVID of $7.3 million for the third quarter of 2021 and $18.5 million for the nine-months ended September 30, 2021, Adjusted EBITDA would have been $8.5 million and $27.6 million, respectively, up 4% and 12% year-over-year.3
- Platform Contribution was $11.0 million for the third quarter of 2021 and $33.9 million for the nine-months ended September 30, 2021, pro forma for the business combination; excluding the aforementioned estimated impacts from COVID, Platform Contribution would have been $18.3 million and $52.4 million, respectively, up 18% and 10% year-over-year.3
Business Highlights
- Reaffirmed prior guidance of approximately 30,000 Medicare Advantage members by the end of 2021, pro forma 2021 revenue of $490 million to $525 million, and pro forma 2021 Adjusted EBITDA of $30 million to $40 million, which includes a $23 million estimated negative impact from COVID.3,4
- Acquired DNF Medical Centers on September 1, adding approximately 4,000 Medicare Advantage members and six medical centers in central Florida.
-
Formalized collaboration with The Related Companies, one of the largest private owners of affordable housing in the United States, to develop senior medical centers in or near affordable housing units owned or affiliated with Related across the country.
- Initial sites expected to open in New York City in the first half of 2022, with additional sites expected in the second half of 2022.
- Announced strategic collaboration with Anthem, with a plan to open approximately 50 de novo medical centers in eight initial states.
- Bolstered core platform and de novo market leadership with the addition of new Market Presidents, a Chief Experience Officer, Chief Compliance Officer, and General Counsel.
- Appointed two new members to the Board of Directors with strong leadership experience in managed care and business process optimization.
1GAAP 2021 financial information includes the activities of IMC Medical Group Holdings, LLC and CareHoldings for the period from June 8, 2021 to (and including) September 30, 2021 (115 days), Senior Medical Associates (SMA) for the period from June 18, 2021 to (and including) September 30, 2021 (105 days), and DNF Medical Centers for the period from September 1, 2021 to (and including) September 30, 2021 (30 days).
2Medical Expense Ratio equals external provider costs divided by Medicare and Medicaid risk-based revenues.
3Adjusted EBITDA and Platform Contribution are non-GAAP financial metrics. A reconciliation of non-GAAP metrics to GAAP financial statements is included in this release.
4Pro forma revenue and Adjusted EBITDA represent run-rate revenue and Adjusted EBITDA based on expected membership at the end of 2021, including all acquisitions expected to be closed by year-end and an estimated $23 million negative from COVID.
Management Commentary
“We are pleased that our third quarter continues to illustrate the effectiveness of our model in delivering proactive and personalized primary healthcare,” said Carlos de Solo, Chief Executive Officer. “By reducing spend from avoidable hospital utilization and investing those dollars back into our whole person health care model, we are closing the loop on the care continuum for some of our nation’s most vulnerable patients while improving clinical outcomes and driving down costs.”
“Our Medical Expense Ratio for the third quarter of 2021 shows that we can grow while maintaining better patient outcomes. As a result, despite headwinds related to COVID and investments in our platform, the fundamentals of our business are performing in line with our forecast, and management is pleased to reaffirm our 2021 guidance. In addition, based on current trends, we expect limited impact to risk-based revenues due to COVID in 2022 and are also optimistic that COVID utilization headwinds will subside in 2022.”
“From a growth perspective, we are pleased to welcome DNF Medical Centers to the CareMax family. Dr. Norberto Fleites, founder of DNF, built a tremendous company, and we are honored to continue to his legacy as we work to expand that platform by implementing our tested care model, increasing enrollments in existing centers, and building new centers.”
“We expect our base business to continue its strong performance while we maintain clear line of sight to opening at least 15 de novo centers in 2022 in New York City, Memphis and other markets. By targeting underserved communities and affordable housing developments, we will continue our focus on improving health disparities for some of the most vulnerable populations, ensuring rewarding careers for our team members and delivering value for our shareholders.”
Conference Call
Management will host a conference call at 8:30 am ET today to discuss the results and business activities. Interested parties may participate in the call by dialing:
(877) 407-9753 (Domestic) or
(201) 493-6739 (International)
The conference call will also be available on the Company's website, ir.caremax.com. Following the live call, a replay will be available on the Company's website.
An investor presentation has also been posted to ir.caremax.com.
About CareMax
CareMax is a technology-enabled care platform providing value-based care and chronic disease management to seniors. CareMax operates medical centers that offer a comprehensive suite of healthcare and social services, and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States. Learn more at www.caremax.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and strategy. Words such as "anticipate," "believe," "budget," "contemplate," "continue," "could," "envision," "estimate," "expect," "guidance," "indicate," "intend," "may," "might," "plan," "possibly," "potential," "predict," "probably," "pro-forma," "project," "seek," "should," "target," or "will," or the negative or other variations thereof, and similar words or phrases or comparable terminology, are intended to identify forward-looking statements. These forward-looking statements reflect the Company’s expectations, plans or forecasts of future events and views as of the date of this press release. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.
Important risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those indicated in forward-looking statements include, among others, the impact of COVID-19 or any variant thereof on the Company's business and results of operation; the availability of sites for medical facilities and the costs of opening such medical facilities; changes in market or industry conditions, regulatory environment, competitive conditions, and receptivity to the Company's services; the Company's ability to continue its growth, including in new markets; changes in laws and regulations applicable to the Company's business, in particular with respect to Medicare Advantage and Medicaid; the Company's ability to maintain its relationships with health plans and other key payers; any delay, modification or cancellation of government contracts; the Company's future capital requirements and sources and uses of cash, including funds to satisfy its liquidity needs; the Company or any other party’s ability to fulfill contractual obligations; and the Company's ability to recruit and retain qualified team members and independent physicians. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's reports filed with the SEC. All information provided in this press release is as of the date hereof, and the Company undertakes no duty to update or revise this information unless required by law, and forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this press release.
Use of Non-GAAP Financial Information
Certain financial information and data contained this press release is unaudited and does not conform to Regulation S-X. Accordingly, such information and data may not be included in, may be adjusted in, or may be presented differently in, any periodic filing, information or proxy statement, or prospectus or registration statement to be filed by the Company with the SEC. Some of the financial information and data contained in this press release, such as Adjusted EBITDA and margin thereof and Platform Contribution and margin thereof, have not been prepared in accordance with United States generally accepted accounting principles (“GAAP”). These non-GAAP measures of financial results are not GAAP measures of our financial results or liquidity and should not be considered as an alternative to net income (loss) as a measure of financial results, cash flows from operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. The Company believes these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. The Company’s management uses these non-GAAP measures for trend analyses and for budgeting and planning purposes.
The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends in and in comparing the Company’s financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. In order to compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. You should review the Company’s audited financial statements, which have been filed by the Company with the SEC.
A reconciliation for Adjusted EBITDA to the most directly comparable GAAP financial measures is included below.
Use of Pro Forma Financial Information and Pro Forma Non-GAAP Financial Information
The unaudited pro forma statements of operations below are provided for informational purposes only and are not necessarily indicative of the operating results or financial position that would have occurred if the acquisitions of IMC and Care Holdings had occurred in the stated historical periods, nor are they indicative of the future results or financial position of the combined company. The unaudited pro forma statements of operations do not give effect to the potential impact, of any anticipated synergies, operating efficiencies or cost savings that may result from the acquisitions of IMC and Care Holdings, any integration costs or tax deductibility of transaction costs.
Additionally, Adjusted EBITDA presented on a pro forma basis gives effect to the acquisitions of IMC and Care Holdings as if they had occurred in historical periods, which does not necessarily reflect what the Company’s Adjusted EBITDA would have been had the acquisitions occurred on the dates indicated. A reconciliation of projected 2021 pro forma Adjusted EBITDA to the most directly comparable GAAP financial measure is not included in this press release because, without unreasonable efforts, the Company is unable to predict with reasonable certainty the amount or timing of non-GAAP adjustments that are used to calculate this non-GAAP financial measure. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company’s future GAAP results.
CAREMAX, INC. |
|||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
|||||||
(in thousands, except share and per share data) |
|||||||
(Unaudited) |
|||||||
|
|
September 30,
|
|
|
December 31,
|
||
ASSETS |
|
|
|
|
|
||
CURRENT ASSETS |
|
|
|
|
|
||
Cash |
|
$ |
80,451 |
|
|
$ |
4,934 |
Accounts receivable, net |
|
|
33,624 |
|
|
|
9,395 |
Inventory |
|
|
398 |
|
|
|
15 |
Prepaid expenses |
|
|
17,926 |
|
|
|
183 |
Risk settlements due from providers |
|
|
464 |
|
|
|
80 |
Due from related parties |
|
|
- |
|
|
|
274 |
Total Current Assets |
|
|
132,863 |
|
|
|
14,881 |
|
|
|
|
|
|
||
Property and equipment, net |
|
|
16,163 |
|
|
|
4,796 |
Goodwill |
|
|
449,470 |
|
|
|
10,068 |
Intangible assets, net |
|
|
61,575 |
|
|
|
8,575 |
Deferred debt issuance costs |
|
|
2,084 |
|
|
|
- |
Other assets |
|
|
1,109 |
|
|
|
183 |
Total Assets |
|
$ |
663,264 |
|
|
$ |
38,503 |
|
|
|
|
|
|
||
LIABILITIES AND STOCKHOLDERS'/MEMBERS' EQUITY |
|
|
|
|
|
||
|
|
|
|
|
|
||
CURRENT LIABILITIES |
|
|
|
|
|
||
Accounts payable |
|
$ |
5,677 |
|
|
$ |
1,044 |
Accrued expenses |
|
|
8,346 |
|
|
|
2,572 |
Accrued interest payable |
|
|
- |
|
|
|
149 |
Risk settlements due to providers |
|
|
171 |
|
|
|
643 |
Current portion of long-term debt |
|
|
6,279 |
|
|
|
1,004 |
Due to related parties |
|
|
- |
|
|
|
39 |
Other current liabilities |
|
|
2,831 |
|
|
|
- |
Total Current Liabilities |
|
|
23,304 |
|
|
|
5,451 |
|
|
|
|
|
|
||
Derivative warrant liabilities |
|
|
17,110 |
|
|
|
- |
Long-term debt, less current portion |
|
|
112,890 |
|
|
|
26,325 |
Other liabilities |
|
|
6,032 |
|
|
|
- |
Total Liabilities |
|
|
159,336 |
|
|
|
31,776 |
COMMITMENTS AND CONTINGENCIES (Note 14) |
|
|
|
|
|
||
STOCKHOLDERS'/MEMBER'S EQUITY |
|
|
|
|
|
||
Class A common stock ($0.0001 par value; 250,000,000 shares
|
|
|
9 |
|
|
|
- |
Additional paid-in-capital |
|
|
506,108 |
|
|
|
- |
Accumulated deficit |
|
|
(2,189 |
) |
|
|
- |
Member units (no par value, 200 authorized, issued and outstanding at
|
|
|
- |
|
|
|
223 |
Members' equity |
|
|
- |
|
|
|
6,504 |
Total Stockholders'/Members' Equity |
|
|
503,928 |
|
|
|
6,727 |
|
|
|
|
|
|
||
Total Liabilities and Stockholders'/Members' Equity |
|
$ |
663,264 |
|
|
$ |
38,503 |
CAREMAX, INC. |
||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||
(Unaudited) |
||||||||||||
(in thousands, except share and per share data) |
||||||||||||
|
Three Months Ended
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
Nine Months Ended
|
|
||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
|
||||
Revenue |
|
|
|
|
|
|
|
|
||||
Medicare risk-based revenue |
$ |
76,428 |
|
$ |
24,242 |
|
$ |
142,005 |
|
$ |
75,083 |
|
Medicaid risk-based revenue |
|
20,884 |
|
|
- |
|
|
26,333 |
|
|
- |
|
Other revenue |
|
7,308 |
|
|
64 |
|
|
9,118 |
|
|
251 |
|
Total Revenue |
|
104,620 |
|
|
24,306 |
|
|
177,456 |
|
|
75,334 |
|
|
|
|
|
|
|
|
|
|
||||
Operating Expenses |
|
|
|
|
|
|
|
|
||||
External provider costs |
|
73,329 |
|
|
17,304 |
|
|
127,023 |
|
|
49,110 |
|
Cost of care |
|
21,602 |
|
|
4,341 |
|
|
34,822 |
|
|
12,244 |
|
Sales and marketing |
|
1,274 |
|
|
311 |
|
|
2,340 |
|
|
811 |
|
Corporate, general and administrative |
|
13,589 |
|
|
1,885 |
|
|
24,264 |
|
|
4,626 |
|
Depreciation and amortization |
|
5,176 |
|
|
359 |
|
|
7,127 |
|
|
1,072 |
|
Acquisition related costs |
|
879 |
|
|
- |
|
|
1,028 |
|
|
- |
|
Total operating expenses |
|
115,849 |
|
|
24,200 |
|
|
196,604 |
|
|
67,863 |
|
Operating income (loss) |
|
(11,229 |
) |
|
106 |
|
|
(19,148 |
) |
|
7,471 |
|
Interest (expense), net |
|
(1,291 |
) |
|
(387 |
) |
|
(2,587 |
) |
|
(1,117 |
) |
Gain on remeasurement of warrant liabilities |
|
10,227 |
|
|
- |
|
|
12,022 |
|
|
- |
|
Gain on extinguishment of debt, net |
|
279 |
|
|
- |
|
|
1,637 |
|
|
- |
|
Other income (expense), net |
|
(840 |
) |
|
- |
|
|
(840 |
) |
|
- |
|
Income (loss) before income tax |
|
(2,854 |
) |
|
(281 |
) |
|
(8,916 |
) |
|
6,354 |
|
Income tax provision (benefit) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
Net income (loss) |
$ |
(2,854 |
) |
$ |
(281 |
) |
$ |
(8,916 |
) |
$ |
6,354 |
|
|
|
|
|
|
|
|
|
|
||||
Net income (loss) attributable to non-controlling interest |
|
- |
|
|
34 |
|
|
- |
|
|
26 |
|
Net income (loss) attributable to controlling interest |
$ |
(2,854 |
) |
$ |
(315 |
) |
$ |
(8,916 |
) |
$ |
6,328 |
|
|
|
|
|
|
|
|
|
|
||||
Net income (loss) attributable to CareMax, Inc. Class A common stockholders |
$ |
(2,854 |
) |
$ |
(315 |
) |
$ |
(8,916 |
) |
$ |
6,328 |
|
Weighted average basic shares outstanding |
|
82,552,520 |
|
|
10,796,069 |
|
|
40,847,294 |
|
|
10,796,069 |
|
Weighted average diluted shares outstanding |
|
82,552,520 |
|
|
10,796,069 |
|
|
40,847,294 |
|
|
10,796,069 |
|
Net income (loss) per share |
|
|
|
|
|
|
|
|
||||
Basic |
$ |
(0.03 |
) |
$ |
(0.03 |
) |
$ |
(0.22 |
) |
$ |
0.59 |
|
Diluted |
$ |
(0.03 |
) |
$ |
(0.03 |
) |
$ |
(0.22 |
) |
$ |
0.59 |
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||
(Unaudited) |
||||||||
(in thousands) |
||||||||
|
|
Nine Months Ended
|
|
|
Nine Months Ended
|
|
||
|
|
2021 |
|
|
2020 |
|
||
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
|
|
||
Net (Loss)/Income |
|
$ |
(8,916 |
) |
|
$ |
6,354 |
|
Adjustments to reconcile net (loss)/income to net cash |
|
|
|
|
|
|
||
(Used in)/provided by operating activities: |
|
|
|
|
|
|
||
Depreciation expense |
|
|
1,657 |
|
|
|
626 |
|
Amortization expense |
|
|
5,488 |
|
|
|
448 |
|
Amortization of debt issuance costs |
|
|
522 |
|
|
|
52 |
|
Stock compensation expense |
|
|
966 |
|
|
|
- |
|
Change in fair value of warrant liabilities |
|
|
(12,022 |
) |
|
|
- |
|
Gain on extinguishment of debt |
|
|
(1,637 |
) |
|
|
- |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
4,296 |
|
|
|
(583 |
) |
Inventory |
|
|
67 |
|
|
|
(3 |
) |
Prepaid expenses |
|
|
(1,371 |
) |
|
|
55 |
|
Risk settlements due from/due to providers |
|
|
(384 |
) |
|
|
(92 |
) |
Due to/from related parties |
|
|
235 |
|
|
|
(141 |
) |
Other assets |
|
|
(312 |
) |
|
|
12 |
|
Accounts payable |
|
|
1,583 |
|
|
|
(347 |
) |
Accrued expenses |
|
|
(3 |
) |
|
|
(381 |
) |
Other liabilities |
|
|
1,178 |
|
|
|
- |
|
Accrued interest |
|
|
(149 |
) |
|
|
- |
|
Net Cash (Used In)/Provided by Operating Activities |
|
|
(8,802 |
) |
|
|
5,998 |
|
|
|
|
|
|
|
|
||
CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
|
|
|
||
Purchase of property and equipment |
|
|
(2,967 |
) |
|
|
(1,789 |
) |
Acquisition of businesses |
|
|
(298,344 |
) |
|
|
(2,656 |
) |
Asset Purchase Agreement Holdback Payment |
|
|
- |
|
|
|
(333 |
) |
Purchase of noncontrolling interest ownership |
|
|
- |
|
|
|
(316 |
) |
Net Cash Used in Investing Activities |
|
|
(301,311 |
) |
|
|
(5,094 |
) |
|
|
|
|
|
|
|
||
CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
|
|
|
||
Borrowings under revolving loan commitment |
|
|
- |
|
|
|
2,467 |
|
Loan from Paycheck Protection Program |
|
|
- |
|
|
|
2,164 |
|
Proceeds from issuance of Class A common stock |
|
|
415,000 |
|
|
|
- |
|
Issuance costs of Class A common stock |
|
|
(12,471 |
) |
|
|
- |
|
Reverse recapitalization |
|
|
(108,386 |
) |
|
|
- |
|
Proceeds from borrowings on long-term debt and credit facilities |
|
|
125,000 |
|
|
|
- |
|
Principal payments on long-term debt |
|
|
(26,143 |
) |
|
|
(251 |
) |
Payment of deferred financing costs |
|
|
(6,883 |
) |
|
|
- |
|
Payment of debt prepayment penalties |
|
|
(487 |
) |
|
|
- |
|
Distributions to members |
|
|
- |
|
|
|
(144 |
) |
Net Cash Provided by Financing Activities |
|
|
385,630 |
|
|
|
4,236 |
|
|
|
|
|
|
|
|
||
NET INCREASE IN CASH |
|
|
75,517 |
|
|
|
5,140 |
|
Cash - Beginning of Period |
|
|
4,934 |
|
|
|
4,438 |
|
CASH - END OF PERIOD |
|
$ |
80,451 |
|
|
$ |
9,578 |
|
Non-GAAP Financial Summary (Unaudited*) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
$'000s |
March 31,
|
|
June 30,
|
|
September
|
|
December
|
|
March 31,
|
|
June 30,
|
|
September
|
|
|||||||
Medicare Risk Revenue |
$ |
63,373 |
|
$ |
62,040 |
|
$ |
63,188 |
|
$ |
65,210 |
|
$ |
65,394 |
|
$ |
66,618 |
|
$ |
76,428 |
|
Medicaid Risk Revenue |
|
10,827 |
|
|
14,828 |
|
|
20,565 |
|
|
19,062 |
|
|
18,897 |
|
|
20,454 |
|
|
20,884 |
|
Other Revenue |
|
4,608 |
|
|
4,126 |
|
|
3,351 |
|
|
3,801 |
|
|
4,127 |
|
|
4,839 |
|
|
7,308 |
|
Total Revenue |
|
78,808 |
|
|
80,994 |
|
|
87,104 |
|
|
88,073 |
|
|
88,418 |
|
|
91,911 |
|
|
104,620 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
External Provider Costs |
|
53,472 |
|
|
52,780 |
|
|
60,158 |
|
|
57,775 |
|
|
60,278 |
|
|
70,466 |
|
|
73,329 |
|
Cost of Care |
|
11,246 |
|
|
10,093 |
|
|
11,417 |
|
|
12,446 |
|
|
13,427 |
|
|
13,246 |
|
|
20,315 |
|
Platform Contribution |
|
14,090 |
|
|
18,121 |
|
|
15,529 |
|
|
17,852 |
|
|
14,712 |
|
|
8,199 |
|
|
10,976 |
|
Platform Contribution Margin (%) |
|
17.9 |
% |
|
22.4 |
% |
|
17.8 |
% |
|
20.3 |
% |
|
16.6 |
% |
|
8.9 |
% |
|
10.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Sales and Marketing |
$ |
1,057 |
|
$ |
1,245 |
|
$ |
1,290 |
|
$ |
1,431 |
|
$ |
391 |
|
$ |
1,688 |
|
$ |
1,274 |
|
Corporate, General and Administrative |
|
7,858 |
|
|
5,667 |
|
|
6,069 |
|
|
6,519 |
|
|
7,197 |
|
|
6,347 |
|
|
8,668 |
|
Adjusted EBITDA |
|
5,175 |
|
|
11,209 |
|
|
8,170 |
|
|
9,901 |
|
|
7,124 |
|
|
163 |
|
|
1,034 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
De Novo Losses |
|
3 |
|
|
24 |
|
|
68 |
|
|
484 |
|
|
184 |
|
|
364 |
|
|
195 |
|
Adjusted EBITDA |
$ |
5,178 |
|
$ |
11,233 |
|
$ |
8,237 |
|
$ |
10,385 |
|
$ |
7,308 |
|
$ |
527 |
|
$ |
1,229 |
|
Adjusted EBITDA Margin (%) |
|
6.6 |
% |
|
13.9 |
% |
|
9.5 |
% |
|
11.8 |
% |
|
8.3 |
% |
|
0.6 |
% |
|
1.2 |
% |
* Figures give effect to the Business Combinations of IMC and Care Holdings as if they had occurred in historical periods. Figures may not sum due to rounding. |
|
||||||||||||||||||||
*Figures may not sum due to rounding
Nine Months Ended September 30, 2021 compared to Nine Months Ended September 30, 2020 Non-GAAP Financial Summary (Unaudited*) |
|
||||||||||
|
Nine Months Ended |
|
|||||||||
|
September 30, 2021 |
|
|
September 30, 2020 |
|
|
Y/Y Change |
|
|||
$'000s |
|
|
|
|
|
|
|
|
|||
Medicare Risk Revenue |
$ |
208,440 |
|
|
$ |
188,601 |
|
|
$ |
19,839 |
|
Medicaid Risk Revenue |
|
60,235 |
|
|
|
46,220 |
|
|
|
14,016 |
|
Other Revenue |
|
16,274 |
|
|
|
12,085 |
|
|
|
4,189 |
|
Total Revenue |
|
284,949 |
|
|
|
246,906 |
|
|
|
38,044 |
|
|
|
|
|
|
|
|
|
|
|||
External Provider Costs |
|
204,073 |
|
|
|
166,411 |
|
|
|
(37,663 |
) |
Cost of Care |
|
46,988 |
|
|
|
32,755 |
|
|
|
(14,233 |
) |
Platform Contribution |
|
33,887 |
|
|
|
47,740 |
|
|
|
(13,853 |
) |
Platform Contribution Margin (%) |
|
11.9 |
% |
|
|
19.3 |
% |
|
|
(7.4 |
%) |
|
|
|
|
|
|
|
|
|
|||
Sales and Marketing |
$ |
3,354 |
|
|
$ |
3,592 |
|
|
$ |
238 |
|
Corporate, General and Administrative |
|
22,212 |
|
|
|
19,594 |
|
|
|
(2,618 |
) |
Adjusted EBITDA |
|
8,321 |
|
|
|
24,554 |
|
|
|
(16,233 |
) |
|
|
|
|
|
|
|
|
|
|||
De Novo Losses |
|
743 |
|
|
|
94 |
|
|
|
649 |
|
Adjusted EBITDA |
$ |
9,064 |
|
|
$ |
24,648 |
|
|
$ |
(15,584 |
) |
Adjusted EBITDA Margin (%) |
|
3.2 |
% |
|
|
10.0 |
% |
|
|
(6.8 |
%) |
* Figures give effect to the Business Combinations of IMC and Care Holdings as if they had occurred in historical periods. Figures may not sum due to rounding. |
|
||||||||||
*Figures may not sum due to rounding
Non-GAAP Operating Metrics* |
March 31,
|
|
June 30,
|
|
September
|
|
December
|
|
March 31,
|
|
June 30,
|
|
September
|
|
|||||||
Centers |
|
21 |
|
|
21 |
|
|
22 |
|
|
24 |
|
|
24 |
|
|
34 |
|
|
40 |
|
Markets |
|
1 |
|
|
1 |
|
|
1 |
|
|
1 |
|
|
1 |
|
|
1 |
|
|
1 |
|
Patients (MCREM)** |
|
24,800 |
|
|
27,500 |
|
|
29,000 |
|
|
28,400 |
|
|
29,200 |
|
|
35,300 |
|
|
40,400 |
|
At-Risk |
|
84.8 |
% |
|
86.7 |
% |
|
85.6 |
% |
|
87.7 |
% |
|
87.0 |
% |
|
84.1 |
% |
|
87.2 |
% |
Platform Contribution ($, Millions)*** |
$ |
14.1 |
|
$ |
18.1 |
|
$ |
15.5 |
|
$ |
17.9 |
|
$ |
14.7 |
|
$ |
8.2 |
|
$ |
11.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
* Figures give effect to the Business Combinations of IMC and Care Holdings as if they had occurred in historical periods. Figures may not sum due to rounding. |
|
||||||||||||||||||||
** MCREM defined as Medicare Equivalent Members, which assumes the level of support received by a Medicare patient is equivalent to that received by three Medicaid or Commercial patients. |
|
||||||||||||||||||||
*** Platform contribution defined as revenue less external provider costs and cost of care, excluding depreciation and amortization. |
|
||||||||||||||||||||
*Figures may not sum due to rounding
Reconciliation to Adjusted EBITDA* |
|||||||||||||||||||||
$'000s |
March 31,
|
|
June 30,
|
|
September
|
|
December 31,
|
|
March 31,
|
|
June 30,
|
|
September 30,
|
|
|||||||
Net Income (Loss) |
$ |
3,170 |
|
$ |
3,466 |
|
$ |
(281 |
) |
$ |
1,218 |
|
$ |
1,302 |
|
$ |
(7,363 |
) |
$ |
(2,854 |
) |
GAAP Pro Forma Adjustments |
|
(3,513 |
) |
|
160 |
|
|
(189 |
) |
|
1,912 |
|
|
(2,730 |
) |
|
(6,186 |
) |
|
(0 |
) |
Pro Forma Net Income |
$ |
(343 |
) |
$ |
3,626 |
|
$ |
(470 |
) |
$ |
3,130 |
|
$ |
(1,429 |
) |
$ |
(13,549 |
) |
$ |
(2,854 |
) |
Interest expense, net |
|
1,658 |
|
|
1,689 |
|
|
1,656 |
|
|
1,628 |
|
|
1,400 |
|
|
1,667 |
|
|
1,291 |
|
Depreciation and amortization |
|
3,514 |
|
|
3,244 |
|
|
3,368 |
|
|
3,418 |
|
|
2,979 |
|
|
3,339 |
|
|
5,176 |
|
Loss/(Gain) on remeasurement of warrant liabilities |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(1,795 |
) |
|
(10,227 |
) |
Loss/(Gain) on extinguishment of debt |
|
- |
|
|
- |
|
|
- |
|
|
451 |
|
|
- |
|
|
806 |
|
|
(279 |
) |
Other expense/(income) |
|
(2 |
) |
|
(12 |
) |
|
100 |
|
|
(997 |
) |
|
212 |
|
|
(2,367 |
) |
|
840 |
|
EBITDA |
$ |
4,827 |
|
$ |
8,547 |
|
$ |
4,653 |
|
$ |
7,630 |
|
$ |
3,162 |
|
$ |
(11,900 |
) |
$ |
(6,053 |
) |
Other adjustments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Non-recurring expenses |
|
(309 |
) |
|
1,985 |
|
|
2,763 |
|
|
1,390 |
|
|
2,795 |
|
|
8,257 |
|
|
4,249 |
|
Acquisition costs |
|
656 |
|
|
678 |
|
|
789 |
|
|
893 |
|
|
1,168 |
|
|
3,806 |
|
|
1,871 |
|
Stock based compensation |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
966 |
|
De novo losses |
|
3 |
|
|
24 |
|
|
68 |
|
|
484 |
|
|
184 |
|
|
364 |
|
|
195 |
|
Discontinued operations |
|
- |
|
|
(0 |
) |
|
(35 |
) |
|
(12 |
) |
|
(1 |
) |
|
(0 |
) |
|
- |
|
Adjusted EBITDA |
$ |
5,178 |
|
$ |
11,233 |
|
$ |
8,237 |
|
$ |
10,385 |
|
$ |
7,308 |
|
$ |
527 |
|
$ |
1,229 |
|
* Pro Forma figures give effect to the Business Combinations of IMC and Care Holdings as if they had occurred in historical periods. Figures may not sum due to rounding. |
|
||||||||||||||||||||
*Figures may not sum due to rounding
Three and Nine months Ended September 30, 2021 Reconciliation to Adjusted EBITDA
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||||||||||
$'000s |
|
September
|
|
|
September
|
|
|
Y/Y Change |
|
|
September
|
|
|
September
|
|
|
Y/Y Change |
|
||||||
Net Income (Loss) |
|
$ |
(2,854 |
) |
|
$ |
(281 |
) |
|
$ |
(2,573 |
) |
|
$ |
(8,916 |
) |
|
$ |
6,354 |
|
|
$ |
(15,269 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
GAAP Pro Forma Adjustments |
|
|
(505 |
) |
|
|
(189 |
) |
|
|
(316 |
) |
|
|
(8,917 |
) |
|
|
(3,541 |
) |
|
|
(5,376 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Pro Forma Net Income (Loss) |
|
|
(3,358 |
) |
|
|
(470 |
) |
|
|
(2,888 |
) |
|
|
(17,832 |
) |
|
|
2,813 |
|
|
|
(20,645 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Interest expense |
|
|
1,291 |
|
|
|
1,656 |
|
|
|
(364 |
) |
|
|
4,358 |
|
|
|
5,002 |
|
|
|
(644 |
) |
Depreciation and amortization |
|
|
5,680 |
|
|
|
3,368 |
|
|
|
2,313 |
|
|
|
11,494 |
|
|
|
10,126 |
|
|
|
1,368 |
|
Loss/(Gain) on remeasurement of warrant liabilities |
|
|
(10,227 |
) |
|
|
- |
|
|
|
(10,227 |
) |
|
|
(12,022 |
) |
|
|
- |
|
|
|
(12,022 |
) |
Loss/(Gain) on extinguishment of debt |
|
|
(279 |
) |
|
|
- |
|
|
|
(279 |
) |
|
|
(1,637 |
) |
|
|
- |
|
|
|
(1,637 |
) |
Other expenses |
|
|
840 |
|
|
|
100 |
|
|
|
740 |
|
|
|
849 |
|
|
|
86 |
|
|
|
763 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
EBITDA |
|
|
(6,052 |
) |
|
|
4,653 |
|
|
|
(10,705 |
) |
|
|
(14,790 |
) |
|
|
18,027 |
|
|
|
(32,817 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Other Adjustments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Non-recurring expenses |
|
|
4,249 |
|
|
|
2,763 |
|
|
|
1,486 |
|
|
|
15,302 |
|
|
|
4,439 |
|
|
|
10,863 |
|
Acquisition costs |
|
|
1,871 |
|
|
|
789 |
|
|
|
1,083 |
|
|
|
6,844 |
|
|
|
2,123 |
|
|
|
4,721 |
|
Stock based compensation |
|
|
966 |
|
|
|
- |
|
|
|
966 |
|
|
|
966 |
|
|
|
- |
|
|
|
966 |
|
De novo losses |
|
|
195 |
|
|
|
68 |
|
|
|
127 |
|
|
|
743 |
|
|
|
94 |
|
|
|
649 |
|
Discontinued operations |
|
|
- |
|
|
|
(35 |
) |
|
|
35 |
|
|
|
(1 |
) |
|
|
(35 |
) |
|
|
34 |
|
Adjusted EBITDA |
|
$ |
1,229 |
|
|
$ |
8,237 |
|
|
$ |
(7,009 |
) |
|
$ |
9,064 |
|
|
$ |
24,648 |
|
|
$ |
(15,584 |
) |
*Pro Forma figures give effect to the Business Combinations of IMC and Care Holdings as if they had occurred in historical periods. Figures may not sum due to rounding. |
|
|||||||||||||||||||||||
*Figures may not sum due to rounding
View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005688/en/
Contacts
CareMax, Inc.
Media
Christine Bucan
(305) 542-8855
Christine@thinkbsg.com
Investor Relations
Ben Quirk
(415) 640-3715
ben.quirk@caremax.com
The Equity Group Inc.
Devin Sullivan
(212) 836-9608
dsullivan@equityny.com
